Sorted By:

Relevance


New Research: Access and quality implications of CMS proposed Part B model

PhRMA  |  Blog Post

Discern Health identified several gaps and risks in the Part B Drug Payment Model design, including: The mandatory participation requirement, which could disrupt care delivery that is already complex for many patients; A lack of necessary quality measures available to capture patient-reported quality outcomes; A failure to evaluate the impact on outcomes, such as survival and quality of life; and The broad scope of the model, which will necessitate immense resources for adequate monitoring and evaluation.
http://catalyst.phrma.org/new-research-access-and-quality-implications-of-cms-proposed-part-b-model

Preventive Care And High Deductibles Work At Cross Purposes, Covered Cal Chief Says

Access Better Coverage  |  From Our Network

“Employers and health plans in the public sector have benefit designs that directly conflict with the goal of the ACA.
http://www.accessbettercoverage.org/social-news/preventive-care-and-high-deductibles-work-at-cross-purposes-covered-cal-chief-says

PhRMA Reports 836 Medicines and Vaccines in Development to Treat Cancer

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
https://www.phrma.org/press-release/phrma-reports-836-medicines-and-vaccines-in-development-to-treat-cancer

Researchers and Patient Advocates Honored with PhRMA Award

PhRMA  |  Press Release

The nominations were reviewed and discussed at length and chosen by a group of individuals with extensive knowledge and experience in the science and patient advocacy fields. 
https://www.phrma.org/press-release/researchers-and-patient-advocates-honored-with-phrma-award

The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

PhRMA  |  Blog Post

The biopharmaceutical industry is committed to continuing research efforts to enhance treatments, find a cure and provide hope to millions of patients and their families worldwide.
http://catalyst.phrma.org/the-war-on-alzheimers-progress-and-challenges-of-biopharmaceutical-research

PhRMA Statement on MedPAC April Recommendations and Vote

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
https://www.phrma.org/press-release/phrma-statement-on-medpac-april-recommendations-and-vote

Medicare Monday: Part D coverage then and now

PhRMA  |  Blog Post

This week, we’re wrapping up our Part D then and now with a closer look at coverage.
http://catalyst.phrma.org/medicare-monday-part-d-coverage-then-and-now

New video: Saving lives and building for the future

PhRMA  |  Blog Post

Watch our new video and visit www.phrma.og/cost to learn more about the value medicines provide to patients and their families.
http://catalyst.phrma.org/new-video-saving-lives-and-building-for-the-future

How modernizing FDA regulations can benefit patients, providers and payers

PhRMA  |  Blog Post

Commitment to Provide Appropriate Context About Data: Communications should clearly disclose appropriate contextual information about data that are presented, including limitations on statistical methods and study design, to ensure that health care professionals and payers are clearly informed about emerging data on the safety, effectiveness and value of medicines.
http://catalyst.phrma.org/how-modernizing-fda-regulations-can-benefit-patients-providers-and-payers

Castellani and Molineaux OpEd in Patriot News

PhRMA  |  Blog Post

And Pennsylvanians are no strangers to medical innovation."
http://catalyst.phrma.org/castellani-and-molineaux-oped-in-patriot-news

Part D Reduced Costs and Improved Access to Medicines for Beneficiaries Previously Without Coverage and for Disabled Beneficiaries

Chartpack  |  From Our Network

Part D reduced costs and improved access to medicines for beneficiaries. 
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-d-reduced-costs-and-improved-access-to-medicines-for-beneficiaries-previously-without-coverage-and-for-disabled-beneficiaries

Panel Discussion and New Report Highlight Benefit of Vermont Clinical Trials for Patients, State Economy

PhRMA  |  Press Release

"Greater awareness and understanding about clinical trials would allow them to explore participating in the research, and the new report provides a helpful step for getting more information about Vermont’s active trials." 
https://www.phrma.org/press-release/panel-discussion-and-new-report-highlight-benefit-of-vermont-clinical-trials-for-patients-state-economy

Modern Doctors’ House Calls: Skype Chat And Fast Diagnosis

From Hope To Cures  |  From Our Network

“We think it’s the future, and it’s here now.
http://www.fromhopetocures.org/modern-doctors-house-calls-skype-chat-and-fast-diagnosis

PhRMA Statement on ASPE Issue Brief on Medicare Part B Drugs and Proposed Part B Changes

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
https://www.phrma.org/press-release/phrma-statement-on-aspe-issue-brief-on-medicare-part-b-drugs-and-proposed-part-b-changes

PhRMA and EFPIA Applaud Push for EU-US Trade Agreement

PhRMA  |  Press Release

Through its direct membership of 31 national associations and 35 leading pharmaceutical companies, EFPIA provides the voice of 2,000 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.
https://www.phrma.org/press-release/phrma-and-efpia-applaud-push-for-eu-us-trade-agreement

PhRMA Statement on Sustainability & Manufacturing Process

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-sustainability-and-manufacturing-process

PhRMA Statement Regarding Research Partnerships and Clinical Trials

PhRMA  |  Press Release

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives.
https://www.phrma.org/press-release/phrma-statement-regarding-research-partnerships-and-clinical-trials

Part D Expanded Coverage and Improved Treatment Adherence for Seniors

Chartpack  |  From Our Network

As a result of Part D, 90% of Medicare beneficiaries have comprehensive drug coverage, and previously uninsured patients with heart failure are more likely to be adherent to their heart treatment regimens. 
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-d-expanded-coverage-and-improved-treatment-adherence-for-seniors

New report provides recommendations for securing and protecting IP

PhRMA  |  Blog Post

That’s why we applaud IPEC for working to protect IP and championing future innovation, creativity and enterprise.
http://catalyst.phrma.org/new-report-provides-recommendations-for-securing-and-protecting-ip

Biologics & Biosimilars

PhRMA  |  From PhRMA

To facilitate effective pharmacogilivance, support appropriate patient care, and facilitate reimbursement, CMS should provide for a separate HCPCS billing codes and reimbursement for each biosimilar biologic product.
https://www.phrma.org/advocacy/research-development/biologics-biosimilars

Combination of Vague Rules Defining a Patient and Lack of Enforcement Leads to Program Abuse

Chartpack  |  From Our Network

The lack of an appropriate patient definition means hospitals can profit from 340B discounts for patients whose prescriptions should not qualify for 340B....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/combination-of-vague-rules-defining-a-patient-and-lack-of-enforcement-leads-to-program-abuse

100 Medicines and Vaccines in Development for HIV/AIDS

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.3 billion in 2009.
https://www.phrma.org/press-release/100-medicines-and-vaccines-in-development-for-hiv/aids

The Biopharmaceutical Research and Development Process

Chartpack  |  From Our Network

From drug discovery through FDA approval, developing a new medicine on average takes at least 10 years and costs an estimated $2.6 billion.
http://chartpack.phrma.org/biophrma-chartpack/research-and-development/the-biopharmaceutical-research-and-development-process

Helping patients is what drives America’s biopharmaceutical researchers and scientists

From Hope To Cures  |  From Our Network

...
http://www.fromhopetocures.org/video/helping-patients-is-what-drives-america-s-biopharmaceutical-researchers-and-scientists

Special Edition Fact Check Friday: Why disclosing negotiated discounts and rebates won’t help patients

PhRMA  |  Blog Post

The bottom line is private negotiations between PBMs and manufacturers drive our competitive marketplace and provide patients with access to a broad range of innovative medicines and foster the development of new treatments and cures patients desperately need.
http://catalyst.phrma.org/special-edition-fact-check-friday-why-disclosing-negotiated-discounts-and-rebates-wont-help-patients

You have reviewed the first 225 results out of 2506. Each page contains 25 results. You're on page 9.

prev 7 8 9 10 11 12 next